The major histocompatibility complex class I (MHC-I) antigen presentation pathway is central to the adaptive immune response. In this process, intracellular proteins are degraded primarily by the ...
A new technology to increase visibility of cancer cells to the immune system using CRISPR has been developed, and could lead to a new way to treat cancer. Major histocompatibility complex (MHC) class ...
Recent analyses show that Omicron variants of SARS-CoV-2 more strongly suppress major histocompatibility complex class I expression than previous versions of the virus. Throughout the pandemic, the ...
Researchers in Japan and the United States have developed a new technology to increase visibility of cancer cells to the immune system using CRISPR. The findings were led by Koichi Kobayashi, ...
ProImmune Ltd, a global leader in life science reagents and services, today announced the launch of its new ProVE ® SL Self-Loading MHC Class I Monomers. The novel reagents for antigen-specific CD8+ T ...
Analysis of primary and acquired resistance to cetuximab from multiomic data in the New EPOC trial. This is an ASCO Meeting Abstract from the 2023 ASCO Annual Meeting I. This abstract does not include ...
Adaptative immune response mediated by NKG2D receptor and its ligand NKG2DL could be the clue for CD8-expressing “killer” T cells to kill tumors lacking the major histocompatibility complex (MHC) ...
A phase I trial of a multi-epitope cancer vaccine (EP-2101) in non-small cell lung (NSCLC) and colon cancer patients ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results